898 related articles for article (PubMed ID: 34620838)
1. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
Li K; Shi H; Zhang B; Ou X; Ma Q; Chen Y; Shu P; Li D; Wang Y
Signal Transduct Target Ther; 2021 Oct; 6(1):362. PubMed ID: 34620838
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
3. Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.
Chen Z; Yuan R; Hu S; Yuan W; Sun Z
Front Immunol; 2022; 13():817942. PubMed ID: 35154134
[TBL] [Abstract][Full Text] [Related]
4. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells-new and exciting players in lung cancer.
Yang Z; Guo J; Weng L; Tang W; Jin S; Ma W
J Hematol Oncol; 2020 Jan; 13(1):10. PubMed ID: 32005273
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.
Krishnamoorthy M; Gerhardt L; Maleki Vareki S
Cells; 2021 May; 10(5):. PubMed ID: 34065010
[TBL] [Abstract][Full Text] [Related]
7. Targeting myeloid-derived suppressor cells for cancer immunotherapy.
Liu Y; Wei G; Cheng WA; Dong Z; Sun H; Lee VY; Cha SC; Smith DL; Kwak LW; Qin H
Cancer Immunol Immunother; 2018 Aug; 67(8):1181-1195. PubMed ID: 29855694
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.
Yang Y; Li C; Liu T; Dai X; Bazhin AV
Front Immunol; 2020; 11():1371. PubMed ID: 32793192
[TBL] [Abstract][Full Text] [Related]
10. Suppression of T cells by myeloid-derived suppressor cells in cancer.
Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
[TBL] [Abstract][Full Text] [Related]
11. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
Li BH; Garstka MA; Li ZF
Mol Immunol; 2020 Jan; 117():201-215. PubMed ID: 31835202
[TBL] [Abstract][Full Text] [Related]
12. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
Front Immunol; 2018; 9():398. PubMed ID: 29552012
[TBL] [Abstract][Full Text] [Related]
13. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
Qu P; Wang LZ; Lin PC
Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
[TBL] [Abstract][Full Text] [Related]
14. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-derived suppressor cells as effectors of immune suppression in cancer.
Pyzer AR; Cole L; Rosenblatt J; Avigan DE
Int J Cancer; 2016 Nov; 139(9):1915-26. PubMed ID: 27299510
[TBL] [Abstract][Full Text] [Related]
16. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
17. The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients.
Tobin RP; Davis D; Jordan KR; McCarter MD
J Leukoc Biol; 2017 Aug; 102(2):381-391. PubMed ID: 28179538
[TBL] [Abstract][Full Text] [Related]
18. Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity.
Kramer ED; Abrams SI
Front Immunol; 2020; 11():1963. PubMed ID: 32983128
[TBL] [Abstract][Full Text] [Related]
19. The downregulation of type I IFN signaling in G-MDSCs under tumor conditions promotes their development towards an immunosuppressive phenotype.
Sun Y; Han X; Shang C; Wang Y; Xu B; Jiang S; Mo Y; Wang D; Ke Y; Zeng X
Cell Death Dis; 2022 Jan; 13(1):36. PubMed ID: 35013108
[TBL] [Abstract][Full Text] [Related]
20. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
Zhao Y; Du J; Shen X
Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
